MedPath

MRI study to prepare for adaptive MRI-guided radiation of prostate carcinoma

Conditions
prostate carcinoma
Registration Number
NL-OMON20274
Lead Sponsor
Radiotherapiegroep
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
10
Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
•Patients with a low to intermediate risk localized PCa confirmed by biopsy and scheduled for curative intent EBRT at RTG;
•= 18 years;
•No transurethral resection of the prostate (TURP) in the last 3 months;
•No anorectal surgery in the past or other situations in which the anorectal anatomy is abnormal;
•No hip prosthesis;
•Meet all MRI safety criteria for MRI at 1.5T according to the protocol of the department of Radiology;
•Written informed consent.

Exclusion Criteria

•V18 years;
•Transurethral resection of the prostate (TURP) in the last 3 months;
•Anorectal surgery in the past or other situations in which the anorectal anatomy is abnormal;
•Hip prosthesis;
•No compliance with all MRI safety criteria for MRI at 1.5T according to the protocol of the department of Radiology;
•No written informed consent.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
oD2cc of the rectum (the minimum dose in 2cc of the rectum receiving the highest dose) and the mean difference in D2cc between the traditional and the online adaptive protocol. <br>oD2cc of the bladder (the minimum dose in 2cc of the bladder receiving the highest dose) and the mean difference in D2cc between the traditional and the online adaptive protocol.
Secondary Outcome Measures
NameTimeMethod
oD99% and D95% CTV prostate<br>oD50% of the rectum and bladder<br>oDmean of the anal canal<br>oD2cc of the small bowel <br>Dx% is the minimum dose to the highest irradiated x% volume of the volume of interest.
© Copyright 2025. All Rights Reserved by MedPath